floxuridine has been researched along with Prostatic Neoplasms in 19 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer (HRPC)." | 2.73 | Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. ( Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y, 2008) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | 2.41 | Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "To improve the management of advanced prostate cancer, one should examine the benefits of adding other agents to docetaxel." | 1.33 | Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. ( Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G, 2006) |
| "Thapsigargin (TG) treatment of rapidly growing androgen independent prostatic cancer cells arrests such cells in G0 and induces their programmed death." | 1.30 | Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. ( Cisek, L; Denmeade, SR; Isaacs, JT; Lin, XS, 1997) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mhaka, A | 1 |
| Denmeade, SR | 3 |
| Yao, W | 1 |
| Isaacs, JT | 5 |
| Khan, SR | 1 |
| Ghosh, S | 1 |
| Salsbury, FR | 1 |
| Horita, DA | 1 |
| Gmeiner, WH | 1 |
| Zimmermann, A | 1 |
| Walt, H | 1 |
| Haller, U | 1 |
| Baas, P | 1 |
| Klein, SD | 1 |
| Li, Y | 1 |
| Hussain, M | 1 |
| Sarkar, SH | 1 |
| Eliason, J | 1 |
| Li, R | 1 |
| Sarkar, FH | 1 |
| Fischel, JL | 2 |
| Ferrero, JM | 2 |
| Formento, P | 2 |
| Ciccolini, J | 2 |
| Renée, N | 1 |
| Formento, JL | 1 |
| Milano, G | 2 |
| Wada, Y | 1 |
| Kikuchi, K | 1 |
| Takahashi, W | 1 |
| Honda, J | 1 |
| Nakanishi, J | 1 |
| Matsumoto, K | 1 |
| Kuwahara, T | 1 |
| Kai, N | 1 |
| Kikukawa, H | 1 |
| Ueda, S | 1 |
| Creaven, PJ | 1 |
| Madajewicz, S | 1 |
| Mittelman, A | 1 |
| Oberfield, RA | 1 |
| Furuya, Y | 1 |
| Lin, XS | 2 |
| Cisek, L | 1 |
| Tombal, B | 1 |
| Cattaneo-Pangrazzi, RM | 3 |
| Schott, H | 3 |
| Wunderli-Allenspach, H | 2 |
| Rothen-Rutishauser, B | 1 |
| Guenthert, M | 1 |
| Schwendener, RA | 3 |
| Derighetti, M | 1 |
| Kobayashi, M | 1 |
| Wood, PA | 1 |
| Hrushesky, WJ | 1 |
| Carter, SK | 1 |
| Wasserman, TH | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Kyprianou, N | 1 |
2 reviews available for floxuridine and Prostatic Neoplasms
| Article | Year |
|---|---|
New potential treatment modalities for disseminated prostatic cancer.
Topics: Androgen Antagonists; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic A | 1984 |
Circadian chemotherapy for gynecological and genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm; | 2002 |
1 trial available for floxuridine and Prostatic Neoplasms
| Article | Year |
|---|---|
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Pro | 2008 |
16 other studies available for floxuridine and Prostatic Neoplasms
| Article | Year |
|---|---|
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Topics: Cell Death; Drug Delivery Systems; Floxuridine; Humans; Hydrolysis; Male; Peptide Fragments; Prodrug | 2002 |
Cooperative stabilization of Zn(2+):DNA complexes through netropsin binding in the minor groove of FdU-substituted DNA.
Topics: Antineoplastic Agents; Binding Sites; Cations, Divalent; Circular Dichroism; Computer Simulation; Co | 2013 |
Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Basal Cell; Floxuridine; Fluorouracil; Humans; Male; Mesopor | 2003 |
Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridi | 2005 |
Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Dr | 2005 |
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; | 2006 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation.
Topics: Animals; Apoptosis; Cell Division; DNA, Neoplasm; Floxuridine; Gene Expression Regulation, Neoplasti | 1994 |
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1997 |
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, West | 1999 |
Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cytoskeleton; Dimerizat | 2000 |
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Topics: Androgens; Antimetabolites, Antineoplastic; Apoptosis; Biotransformation; Cell Cycle; Cell Division; | 2000 |
Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Nucleus; Cell Size; Dimerization; Dinucleoside Ph | 2000 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
"Thymineless" death in androgen-independent prostatic cancer cells.
Topics: Animals; Blotting, Northern; Cell Line; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antitum | 1989 |